Evidence for renal vasodilation in pre-dialysis patients during correction of anemia by erythropoietin  by Frenken, Leon A.M. et al.
Kidney International, Vol. 41 (1992), pp. 384—387
Evidence for renal vasodilation in pre-dialysis patients during
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Evidence for renal vasodilation in pre-dialysis patients during correc-
tion of anemia by erythropoietln Results from animal experiments have
suggested that treatment with recombinant human erythropoietin
(rHuEPO) causes changes in renal hemodynamics which are detrirnen-
tal to renal function. Therefore, the effects of correction of the anemia
by rHuEPO on glomerular filtration rate (GFR; inulin clearance) and
effective renal plasma flow (ERPF; PAH clearance) were studied in
eight pre-dialysis patients. The studies were done before (Hct 0,24
0.05 liter/liter) and at 89 19 days after the start of rHuEPO therapy
(Hct 0.39 0.03 liter/liter). To further evaluate the effects of ACE
inhibition, 25 mg of captopril was given orally after baseline values had
been obtained. Baseline GFR, renal blood flow (RBF) and filtration
fraction (FF) did not change during rHuEPO therapy. At low hemato-
crit (Hct) captopril induced a significant increase in ERPF and RBF,
and a decrease in MAP. After correction of the hematocrit the blood
pressure lowering effect of captopril remained unchanged. However,
captopril no longer induced changes in ERPF and RBF. We conclude
that the increase in hematocrit had no adverse effects on GFR. The
results suggest that changes in hematocrit may influence the effects of
ACE inhibition on efferent vascular resistance. Therefore, the hemato-
crit should be taken into account when evaluating studies on the effects
of ACE inhibition in the progression of chronic renal failure.
The introduction of recombinant human erythropoietin
(rHuEPO) for the treatment of the anemia of chronic renal
failure has renewed the interest in the effects of changes in
hematocrit on hemodynamics and renal function [1—5]. A major
adverse event associated with rHuEPO therapy is the increase
in blood pressure. The hematocrit is the major determinant of
blood viscosity at high and low rates of shear [6]. The increase
in whole blood viscosity and the loss of hypoxic vasodilation,
resulting in an inappropriate increase in systemic vascular
resistance, are suggested as potential causes of the increased
blood pressure [7].
Besides the adverse effects of systemic hypertension with
regard to renal function, the increased hematocrit by itself also
might affect the rate of progression of renal failure. Efferent
arterioles are smaller in caliber and longer than afferent arteri-
oles. According to Poiseuille's law, the increase in viscosity will
cause a larger rise in efferent than in afferent vascular resis-
tance. Also, due to ultrafiltration of plasma water in the
glomerulus, hematocrit in the efferent arteriole always exceeds
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hematocrit in the afferent arteriole [8]. This results in a dispro-
portionate, passive increase in efferent vascular resistance.
Changes in activity of the renin-angiotensin system also may
play an active role, since plasma renin levels in dogs increase
when hematocrit rises [9].
In agreement with these theoretical considerations, important
effects of hematocrit on renal hemodynamics were observed in
patients with congenital cyanotic heart disease and cor pulmo-
nale [10, 11]. In these patients renal blood flow (RBF), and
effective renal plasma flow (ERPF) were considerably reduced.
Since glomerular filtration rate (GFR) decreased to a smaller
extent, this resulted in an increased filtration fraction (FF).
Alter acute reduction of the hematocrit in these patients, RBF
and ERPF increased, FF fell, and proteinuria decreased. Also
in experimental animals, FF varies directly with systemic
hematocrit, with proportionally greater changes in ERPF than
in GFR [12]. More direct evidence for the influence of hemato-
crit on changes in renal hemodynamics stems from micropunc-
ture studies in rats. An acute increase in hematocrit, induced by
isovolemic exchange transfusions, led to an increase in efferent
arteriolar resistance, an increase in glomerular transcapillary
hydraulic pressure gradient and an increase in FF [13]. These
studies showed that changes in renal arteriolar vascular resis-
tance cause the changes in ERPF and FF in response to
variations in systemic hematocrit. The presence of continuous
glomerular hypertension in the rat may cause the development
of focal segmental glomerular sclerosis and renal failure even
after limited renal ablation [14]. Increased glomerular capillary
pressure also may contribute to the progression of renal failure
in patients with renal disease [15].
Recently, results of two studies in five-sixth riephrectomized
rats treated with rHuEPO suggested that rHuEPO therapy may
accelerate chronic renal failure, and worsen systemic hyperten-
sion and glomerular hypertension because of increased efferent
arteriolar resistance [16, 17]. Up to now, clinical studies in
patients with renal disease, although not specifically designed to
evaluate renal function, did not report acceleration of the rate of
progression of renal failure measured as the slope of inverse
plasma creatinine concentration (l/l'Cr) versus time [2—5]. Yet,
the rate of decline in 11Crmaynot accurately reflect the decline
in GFR.
In the present study, we have investigated the effects of
rHuEPO induced changes in hematocrit on renal function in
pre-dialysis patients.
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Methods
Patients
Eight patients (four females, four males) with a history of
progressive chronic renal failure participated in the study. The
underlying renal diseases were: chronic glonierulonephritis in
three, congenital hypoplastic kidneys in one, chronic pyelone-
phritis in one, reflux nephropathy with uninephrectomy in one,
and unknown renal disease in two patients. The mean (± SD)
Ccr was 13 5 ml/min/l .73 m2. All patients were anemic with
hematocrits ranging between 0.16 and 0.30 liter/liter. The me-
dian age was 33 years (range from 25 to 66 years). Hypertension
was either absent (N = 4) or medically controlled (N = 4).
Antihypertensive treatment consisted of metoprolol 200 mg
daily (patient A), propanolol 3 dd 20 mg (patient C), atenolol 25
mg daily (patient F), or atenolol 25 mg and nifedipine 2 dd 20 mg
(patient G). No ACE inhibitors were prescribed before or
during the study. None of the patients had received blood
transfusions within three months of the start of the study.
Dietary and medication regimens were stable for at least one
month before study entry and attempts were made to keep them
constant. The 24 hour excretion of sodium and urea did not
change during the study period.
Methods
All patients gave written informed consent. The patients were
given intravenous injections of rHuEPO three times a week for
eight weeks. The patients were randomly assigned to receive
either 50 (N 2), 100 (N = 3), or 150 (N 3) units of rHuEPO
per kilogram of body weight. Mter the completion of this eight
week period, rHuEPO was injected intravenously once a week.
The dose was three times the dose given in the former period,
adjusted for response. Renal function measurements were done
before rHuEPO therapy and at 89 19 days after the start of
rHuEPO therapy when the increased hematocrit was stable
within the target range of 0.35 to 0.45 liter/liter for at least three
weeks.
The patients did not take food or drugs from 12 hours before
the start of the renal function measurements until the end of the
study. Smoking was not allowed in the same period. The
patients were in a half sitting position during the whole study,
except for micturition. GFR (inulin clearance) and ERPF (PAH
clearance) were measured using a continuous infusion tech-
nique. An isotonic solution of inulin (mutest0, Laevosan, Linz,
Austria) and para-aminohippuric acid (PAH, Merck Sharp &
Dohme, West Point, Pennsylvania, USA) in distilled water was
used as described elsewhere [181. Blood and urine samples were
simultaneously collected at 45 minute intervals. Prior to the
infusion the patients were given an oral water load of 15 mllkg.
Every next 45 minutes the urinary losses were replaced by an
equivalent oral water load. If urine flow was less than 100 ml/45
mm an extra oral water load of 100 ml was given. Urine was
collected by spontaneous micturition. Mean arterial pressure
(MAP, mm Hg) was measured every 15 minutes using a
calibrated automatic recorder (DynamapTM). The mean MAP of
every 45 minute interval was calculated as the mean of the three
recordings during that interval. Body weight was measured
before and after the study. After having obtained baseline
values, 25 mg of captopril was given orally at 210 minutes after
the start of the infusion, and measurements were continued for
another three hours. The mean value of the two 45-minute GFR
and ERPF measurements obtained immediately before capto-
pril was compared with the mean value of two 45-minute
intervals starting 45 minutes after captopril. Clearances were
calculated according to standard clearance formulas C =UV/P
and expressed as ml per mm per 1.73 m2 body surface. The FF
was calculated as l00• GFRJERPF, and RBF was estimated
using the formula: RBF = ERPF/(l — hematocrit). During
steady state the intraindividual coefficients of variation of the
inulin and PAH clearances were 6.5%, and 6.9%, respectively.
The intraindividual coefficients of variation between two sepa-
rate measurements were 9.6%, and 11.2%, respectively.
All results are expressed as means with standard deviations.
T-test procedures for paired samples and for independent
samples were used for statistical analysis. Differences were
considered significant at the 0.05 level.
Results
rHuEPO therapy increased the mean hematocrit value from
0.24 0.05 liter/liter to 0.39 0.03 liter/liter. In patient C, who
had hypertension before rHuEPO therapy, the dose of pro-
panolol was increased to 3 dd 40 mg after seven weeks of
therapy because of increasing blood pressure. In another hyper-
tensive patient (patient G) nifedipine was replaced by minoxidil
(2 dd 5 mg) after six weeks of rHuEPO due to side effects. All
four patients without antihypertensive medication prior to
rHuEPO therapy remained normotensive. Under these condi-
tions there were no significant changes of systolic, diastolic, or
mean arterial blood pressure throughout the study period.
The individual data on renal function are given in Table 1.
Baseline GFR and FF were comparable before and during
rHuEPO treatment (Table 2). The RBF also remained un-
changed, and the values of ERPF tended to decrease. These
small changes in ERPF correlated well with the changes pre-
dicted from initial RBF and the change in hematocnt (r 0.83,
P < 0.01). Moreover, in two patients in whom hematocrit
values had returned to their initial values after eight months, the
decreased value of ERPF at high hematocrit had also returned
to the initial value, while RBF was unchanged (data not shown).
During rHuEPO therapy there was no significant change in 24
hours proteinuria when compared with pre-treatment values.
Prior to rHuEPO therapy a single dose of 25 mg of captopril
resulted in a significant increase in RBF, when compared to
baseline values (Table 2). Despite a small, but nonsignificant
increase in GFR, FF decreased significantly. Mter correction of
the hematocrit by rHuEPO therapy the blood pressure lowering
effect of captopril was identical to that in the first study.
However, the captopril-induced rise in RBF and ERPF had
disappeared completely. Since GFR remained stable, a change
in FF was also absent. In four patients who were not yet on
dialysis after 35 I weeks of treatment with rHuEPO, the
measurements were repeated. In these patients we observed
that a reaction to captopril was still absent (data not shown). By
contrast, in another patient, in whom hematocrit after eight
months had returned to the initial value, the response to
captopril which was absent during high hematocrit was present
again.
386 Frenken et a!: Renal hemodynamics and erythropoietin
Table 1. Individual data (patients A-H) on renal function and effects of captopril before and after 89 19 days of rHuEPO treatment
Study Period A B C D E F G H
GFR I Baseline 11.6 7.8 7.2 12.0 8.9 3.6 8.5 9.3
After captopril 12.6 6.6 9.2 14.8 9.1 7.1 8.9 8.2
GFR 2 Baseline 8.6 6.9 5.3 14.6 9.3 4.1 6.9 7.4
After captopril 10.2 6.4 6.3 13.2 8.6 4.2 7.1 4.1
ERPF I Baseline 82.5 20.4 44.9 51.3 38.4 22.1 39,5 54.5
After captopril 95.7 19.9 61.1 61.7 44.2 44.6 48.4 52.0
EPRF 2 Baseline 62.8 21.2 27.5 56.3 40.4 25.1 34.2 29.8
After captopril 62.5 21.9 36.8 58.5 40,4 24.3 37.9 15.9
RBF 1 Baseline 107.1 25.2 66.3 71.1 48.1 30.9 47.3 77.6
After captopril 123.8 24.4 87.2 84.2 55.6 61.7 59.0 73.3
RBF 2 Baseline 99,5 34.4 48.5 90.7 62.9 41.0 54.3 54.5
After captopril 98.2 34.7 65.7 96.7 65.7 39.5 60.1 29.7
FF 1 Baseline 14.1 38.0 15.9 23.4 23.2 16.6 21.6 17.1
After captopril 13.2 33.3 15.1 23.9 20.7 15.8 18.4 15.7
FF 2 Baseline 13.8 32.7 19.3 25.9 23.1 16.6 20.1 24.8
After captopril 16.4 29.1 17.2 22.6 21.2 17.0 18.8 26.0
GFR, ERPF, and RBF are expressed in mI/mini! .73 m2; FF — 100 GFRJERPF; RBF = ERPF/(1-hematocrit). The first studies were done before
rHuEPO therapy. The second studies were done after the hematocrit had reached the target range, and was stable for at least three weeks.
Table 2. Mean values of renal function and effects of captopril
before and after 89 19 days of rHuEPO treatment
Before rHuEPO therapy During rHuEPO therapy
Baseline After captopril Baseline After captopril
ERPF
GFR
FF
RBF
MAP
UVAIb
44.2 19.8
8.6 2.6
21.2 7.7
59.2 26.9
111.5 23.3
1.4 1.1
53.5 21,5a.t,
9.6 2.8
19.5 6.5a
71.2 29.0
103.3 21.9a
1.4 1.1
37.2 15.1
7.9 3.2
22.0 6.0
60.7 23.0
110.3 15.8
1.7 1.3
37.3 16.7
7.5 3.1
21.1 4.7
61.3 26.3
103.7 16.6a
1.5 1.3
ERPF, RBF, and GFR are expressed in mI/mm/I .73 m2; FF =
100 GFRIERPF; RBF = ERPF/(1-hematocrit). MAP is expressed in
mm Hg. Albumin excretion (UVAIb) is expressed in mg/mm. The values
are expressed as means so.
a P < 0.05, Difference between parameter before and after captopril'P < 0.05, C p = 0.07, Difference between changes after captopril
before and after rHuEPO therapy
Discussion
Studies in five-sixth nephrectomized rats showed that anemia
retards the development of proteinuna and glomerular injury
and reduces systemic hypertension, whereas treatment with
rHuEPO causes an acceleration of glomerular injury [17]. These
findings suggested that full correction of anemia in pre-dialysis
patients may prove harmful to residual renal function. How-
ever, in rats there was also a considerable rise in systemic blood
pressure during rHuEPO therapy. The remnant kidney model is
a hypertensive model, in which systemic hypertension induces
glomerular capillary hypertension, which is the major factor
contributing to glomerular injury, hyperfiltration being much
less important [14]. In agreement with these findings it was
recently shown that glomerular hyperfiltration was not accom-
panied by glomerular injury in a normotensive rat remnant
kidney model [19]. Whether rHuEPO therapy without concom-
itant hypertension will cause identical injury in experimental
animals has not been studied. Moreover, in the anemia-protec-
tion model the accompanying iron depletion may have pro-
tected against additional tubulointerstitial injury and renal func-
tion deterioration [20].
Recently, a clinical study of rHuEPO therapy in pre-dialysis
patients showed a significant increase in FF (0.27 0.17 to 0.33
0.22) in four weeks [21]. In these patients the mean hemato-
crit was only moderately increased from 0.21 0.025 to 0.27
0.024 liter/liter. More importantly, the mean MAP increased
significantly from 119.3 18.3 to 134.1 15.2 mm Hg. Yet, this
increase in blood pressure was probably also related to the fact
that these patients received no antihypertensive treatment. In
the present study the increase in hematocrit was larger, from
0.24 0.05 to 0.39 0.03 liter/liter in 15.4 3.7 weeks. In our
patients mean blood pressure was lower, and was kept constant
throughout the study. Despite the considerable change in he-
matocrit, no significant alterations of GFR, RBF, or FF were
observed. Although a change in the rate of decline in renal
function cannot be excluded, the results of this and another
study [5] do not suggest that a considerable increase in hema-
tocrit has a major influence on kidney function.
To investigate further the hemodynamic characteristics dur-
ing treatment with rHuEPO, we studied the effects of a single 25
mg dose of captopnl on renal function. We were interested to
see if the expected blocking effect of captopril on angiotensin
Il-mediated efferent vasoconstriction would be influenced by a
change in hematocrit. Before rHuEPO treatment there was a
significant increase in RBF after captopril, with a concomitant
decrease in FF. Surprisingly, after correction of the hematocrit,
captopril no longer induced changes in RBF and FF, although
the blood pressure lowering effect of captopnl was identical to
that in the first study. In our study baseline RBF remained
unchanged, indicating that total renal vascular resistance did
not change. This can be explained by either no change in renal
vascular resistances, or by an increased passive vascular resis-
tance combined with a decreased vascular tone. The observa-
tion that the observed rise in RBF after captopril during anemia
was absent when hematocrit had increased, favors the expla-
nation that, with increasing hematocrit, RBF is maintained by
the development of an efferent vasodilation that cannot be
increased further by captopril. An additional effect of increasing
hematocrit on afferent vascular resistance cannot be excluded.
A captopril-induced efferent vasodilation with high hematoerit
could have been masked by the concomitant decrease in blood
pressure. However, since baseline blood pressure and the
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decrease in blood pressure after captopril were similar before
and alter increasing the hematocrit, the observations still indi-
cate different states. In one patient, in whom hematocrit after
eight months had returned to the initial value, the previously
disappeared response to captopril during high hematocrit was
present again. Since blood pressure, body weight and antihy-
pertensive drugs had not changed, this suggests that the
changes observed are indeed mediated by the change in hema-
tocrit.
One could argue that the PAH clearance does not adequately
reflect renal plasma flow in patients with decreased renal
function due to an incomplete extraction rate. Yet, even when
PAH clearance would not estimate low renal plasma flow
adequately when compared to situations with normal renal
plasma flow, it is likely that changes in renal plasma flow would
still be reflected in changes in PAH clearance.
Results of several animal studies suggest that ACE inhibitors
are beneficial in reducing the rate of decline of GFR, by their
specific effect on efferent vascular resistance, irrespective of
their blood pressure lowering effect [22, 23]. Prospective,
randomized trials using ACE inhibition in patients with renal
disease are currently under way. With regard to these studies,
our data suggest that changes in hematocrit may influence the
effects of ACE inhibition on efferent vascular resistance. There-
fore, the hematocrit should be taken into account when evalu-
ating studies on the effects of ACE inhibition in the progression
of chronic renal failure. Also, treatment with ACE inhibitors for
hypertension developing during rHuEPO therapy would appear
to offer no specific advantages above other antihypertensive
drugs. The final answer to the question whether rHuEPO
changes the natural course of progression of renal failure in
patients with renal disease, can only be given by large prospec-
tive trials, including precise renal function measurements and
appropriate dietary and blood pressure control.
Reprint requests to L.A.M. Frenken, M.D., University Hospital
Njmegen, Department of Medicine, Division of Nephrology, P.O. Box
9101, NL-6500 HB Njjmegen, The Netherlands.
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